Boston Scientific Corporation $BSX Position Reduced by Putney Financial Group LLC

Putney Financial Group LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 28.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,614 shares of the medical equipment provider’s stock after selling 1,040 shares during the period. Putney Financial Group LLC’s holdings in Boston Scientific were worth $281,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific during the first quarter worth about $27,000. Sound Income Strategies LLC raised its position in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares in the last quarter. Princeton Global Asset Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at about $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in shares of Boston Scientific during the 2nd quarter valued at about $37,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 9,990 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $101.13, for a total value of $1,010,288.70. Following the transaction, the director owned 27,035 shares in the company, valued at approximately $2,734,049.55. This represents a 26.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 112,891 shares of company stock worth $11,501,887 in the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

BSX opened at $100.55 on Friday. The firm has a market capitalization of $148.98 billion, a P/E ratio of 53.77, a PEG ratio of 2.02 and a beta of 0.61. The stock has a fifty day moving average of $100.87 and a 200-day moving average of $102.25. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $83.38 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent research reports. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Truist Financial raised their price objective on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Leerink Partners boosted their target price on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.